IMRX vs. ALMS, OGI, LFCR, CGEN, LRMR, AMRN, CTNM, VIRI, ZYBT, and DRUG
Should you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Alumis (ALMS), Organigram (OGI), Lifecore Biomedical (LFCR), Compugen (CGEN), Larimar Therapeutics (LRMR), Amarin (AMRN), Contineum Therapeutics (CTNM), Virios Therapeutics (VIRI), Zhengye Biotechnology (ZYBT), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry.
Immuneering vs.
Immuneering (NASDAQ:IMRX) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings.
67.7% of Immuneering shares are owned by institutional investors. 25.0% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Immuneering presently has a consensus target price of $12.20, indicating a potential upside of 575.90%. Alumis has a consensus target price of $26.57, indicating a potential upside of 413.95%. Given Immuneering's higher probable upside, analysts clearly believe Immuneering is more favorable than Alumis.
In the previous week, Alumis had 5 more articles in the media than Immuneering. MarketBeat recorded 6 mentions for Alumis and 1 mentions for Immuneering. Alumis' average media sentiment score of 0.70 beat Immuneering's score of 0.00 indicating that Alumis is being referred to more favorably in the news media.
Alumis' return on equity of 0.00% beat Immuneering's return on equity.
Alumis has lower revenue, but higher earnings than Immuneering.
Immuneering received 18 more outperform votes than Alumis when rated by MarketBeat users. However, 100.00% of users gave Alumis an outperform vote while only 67.35% of users gave Immuneering an outperform vote.
Summary
Alumis beats Immuneering on 8 of the 13 factors compared between the two stocks.
Get Immuneering News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immuneering Competitors List
Related Companies and Tools
This page (NASDAQ:IMRX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free IMRX Stock Alerts